Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Volatility and Risk
Milestone Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Profitability
This table compares Milestone Pharmaceuticals and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
Analyst Recommendations
This is a breakdown of recent recommendations for Milestone Pharmaceuticals and Sol-Gel Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
Milestone Pharmaceuticals currently has a consensus price target of $6.40, suggesting a potential upside of 866.48%. Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 221.14%. Given Milestone Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than Sol-Gel Technologies.
Valuation and Earnings
This table compares Milestone Pharmaceuticals and Sol-Gel Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Milestone Pharmaceuticals | $1.55 million | 53.19 | -$63.06 million | ($0.69) | -0.96 |
| Sol-Gel Technologies | $1.79 million | 112.17 | -$6.13 million | ($5.64) | -10.90 |
Sol-Gel Technologies has higher revenue and earnings than Milestone Pharmaceuticals. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Sol-Gel Technologies beats Milestone Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders. Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients. Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
